Emergent BioSolutions completes sale of its travel vaccine business

On May 15, 2023, Emergent BioSolutions, the New York Stock Exchange listed developer and manufacturer of vaccines, completed the sale of its travel vaccine business to Bavarian Nordic for an upfront payment of USD 270 million.

Lenz & Staehelin advised Emergent BioSolutions in this transaction.

Published: 16 May 2023
Lenz & Staehelin {PAGENO}/{nbpg}
{PAGENO}/{nbpg}